Project Grant K99DA064784
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a $210,168 Project Grant effective May 1, 2026, through April 30, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This K99/R00 career development award supports basic neuroscience research investigating glutamatergic circuit adaptations underlying opioid use disorder (OUD) and relapse behavior. The funded research will employ two-photon calcium...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $415,250 Project Grant award effective July 1, 2025, through June 30, 2027, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research investigating the role of cortical astroglia in heroin seeking behaviors, utilizing advanced neuroimaging techniques including genetic calcium indicators and two-photon imaging to analyze neuronal...
- Federal Grant Award Summary The University of South Carolina received a $192,149 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded February 1, 2026, with completion scheduled for January 31, 2028. The grant funds research investigating noradrenergic mechanisms underlying stress-induced opioid reinstatement, addressing the neurobiological pathways through which traumatic stress and comorbid neuropsychiatric...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a $249,000 Project Grant on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The three-year award, concluding May 31, 2029, funds research examining how social-contextual stressors—such as financial hardship—impact smoking cessation and relapse among socioeconomically disadvantaged young adults (SDYA). This investigation directly supports...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded July 1, 2026, with completion targeted for June 30, 2028. The award funds research to develop and validate a novel integrated neuroimaging and drug self-administration (SA) system called SORDINO-fMRI that simultaneously captures real-time neuronal activity...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $675,129 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026 through January 31, 2031. The award funds evaluation of COPE-A (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure, Adolescent version), an integrated, trauma-focused intervention specifically adapted for adolescents with...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded $877,500 to the University of California, San Diego for a two-year project (July 15, 2025 through June 30, 2027) investigating neurobiological mechanisms underlying cocaine use disorder (CUD) susceptibility. The project employs a novel polygenic prediction methodology called RATTACA to identify pre-existing cellular differences in gabaergic and...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $181,092 to Icahn School of Medicine at Mount Sinai, with an award date of May 1, 2026 and completion date of April 30, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This grant supports basic neuroscience research investigating the mechanisms by which dopamine receptor type 2 (D2)-expressing cells in the ventral hippocampus (VHPC) control relapse behavior in...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a Project Grant totaling $686,692 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct prospective research on cannabis use reduction and its impact on patient functioning. Initiated on September 1, 2025, and extending through July 31, 2030, this eight-week clinical trial will enroll 176 adults aged 18 and older with Cannabis Use Disorder...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, Santa Barbara $645,966 under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 15, 2026, for a Project Grant extending through March 31, 2031. This award funds preclinical research to advance pharmacological interventions targeting psychostimulant use disorder (PUD), addressing the absence of FDA-approved medications for cocaine and methamphetamine addiction. The...
The Medical University of South Carolina received a $211,680 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into the neurobiological mechanisms underlying substance use disorder (SUD) relapse. Awarded August 1, 2026, with a completion date of July 31, 2028, this two-year project investigates the role of NPAS4-positive neuronal ensembles in reward-cue associations and relapse-like behavior. The research focuses on understanding how the nucleus accumbens—a brain region implicated in drug reward processing—encodes associations between environmental cues and cocaine or natural reward through specific populations of medium spiny neurons expressing dopamine D1 and D2 receptors. The project deliverables include experimental evaluations of the NPAS4-positive neuronal ensemble's role in cue-reinstated cocaine-seeking behavior, characterization of calcium transient dynamics across NPAS4-positive versus NPAS4-negative neurons during multi-phase sucrose and cocaine self-administration paradigms, and identification of reward type-specific ensemble characteristics. By elucidating the underlying mechanisms of drug-cue associations—which affect over 48 million individuals with SUDs in the United States—this research aims to identify novel therapeutic targets for preventing relapse even after prolonged abstinence.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $211.7k | 7/16/26 |